BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:36 PM
 | 
Feb 27, 2019
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA accepts NDA for multiple sclerosis prodrug from Alkermes, Biogen

Alkermes plc (NASDAQ:ALKS) said FDA accepted for review an NDA for diroximel fumarate (BIIB098) to treat relapsing forms of multiple sclerosis. The PDUFA date is in 4Q19. The company submitted the NDA submitted...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >